Welcome to LookChem.com Sign In|Join Free

CAS

  • or

6885-44-5

Post Buying Request

6885-44-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6885-44-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 6885-44-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,8,8 and 5 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 6885-44:
(6*6)+(5*8)+(4*8)+(3*5)+(2*4)+(1*4)=135
135 % 10 = 5
So 6885-44-5 is a valid CAS Registry Number.

6885-44-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name (+)-3-methoxy-1,3,5(10),8-estratetraen-17-one

1.2 Other means of identification

Product number -
Other names 14

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6885-44-5 SDS

6885-44-5Relevant articles and documents

CORTISTATIN ANALOGUES AND SYNTHESES AND USES THEREOF

-

, (2015/07/15)

Provided herein are compounds of Formula (A), (B), (C), (D) and (E), pharmaceutically acceptable salts, quaternary amine salts, and N-oxides thereof, and pharmaceutical compositions thereof. Compounds of Formula (A), (B), (C), (D), and (E) are contemplated useful as therapeutics for treating a wide variety of conditions, e.g., including but not limited to, conditions associated with angiogenesis and with CDK8 and/or CDK19 kinase activity. Further provided are methods of inhibiting CDK8 and/or CDK19 kinase activity, methods of modulating the β-catenin pathway, methods of modulating STAT1 activity, methods of modulating the TGFβ/BMP pathway, methods of modulating HIF-1 -alpha activity in a cell, and methods of increasing BIM expression to induce apoptosis, using a compound of Formula (A), (B), (C), (D), or (E). Further provided are CDK8 and CDK19 point mutants and methods of use thereof.

Total synthesis with a chirogenic opening move demonstrated on steroids with estrane or 18a-homoestrane skeleton

Quinkert,Del Grosso,Doring,Doring,Schenkel,Bauch,Dambacher,Bats,Zimmermann,Durner

, p. 1345 - 1391 (2007/10/02)

A concept of first choice for the synthesis of the title compounds had been proposed by Dane in the late 1930s. It was soon turned down, because the opening move - a chirogenic Diels-Alder reaction - did not work. With Lewis acids as mediators, however, a successful start has been achieved now. With Ti complexes of chelating ligands (Seebach's TADDOLs (= α,α,α',α'-tetraaryl-1,3-dioxolane-4,5-dimethanols)), enantioselective formation of the desired adducts does occur. Efficient total syntheses of 2 and 3a have been accomplished.

Highly selective total synthesis of 19-nor-steroids via a photochemical key reaction: Racemic target compounds

Quinkert,Weber,Schwartz,et al.

, p. 2335 - 2371 (2007/10/02)

-

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 6885-44-5